Arbutus Q2 net loss $5.1M; receives $178M Moderna payment, plans $230M buyback

Arbutus Biopharma Corp

2026-Q2 EPS reported $0.84 revenue$180,140,000

Q2 revenue fell to $1.0M from $10.7M YoY; net loss of $5.1M ($0.03/share) vs net income of $2.5M in 2025.
Received $178.4M from Moderna settlement in July; owns ~16% of Genevant and expects a dividend.
Board authorized up to $230M share repurchase program, may include tender offer, starting Q3 2026.
Filed international patent lawsuits against Pfizer and BioNTech across 21 countries for LNP technology.
FDA granted Fast Track for imdusiran; alignment on Phase 2b design for chronic hepatitis B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.